According to our (Global Info Research) latest study, the global Gene Therapies for Cancer Treatment market size was valued at US$ 11290 million in 2025 and is forecast to a readjusted size of US$ 35710 million by 2032 with a CAGR of 18.1% during review period.
Cancer gene therapy is an innovative treatment approach that involves directly modifying the patient's genome to treat cancer. Common strategies include Chimeric Antigen Receptor T-cell (CAR-T) therapy, gene editing technologies such as CRISPR-Cas9, and viral vector-mediated gene transduction. Compared to traditional chemotherapy and radiotherapy, gene therapies offer higher specificity and personalized advantages by repairing or replacing oncogenes at the molecular level, activating the immune system to recognize and eliminate tumor cells, or enhancing anti-tumor immune responses. Cancer gene therapies are applicable to various cancer types, including hematologic malignancies (such as leukemia and lymphoma) and solid tumors (such as lung and breast cancer). Although challenges remain, such as high costs, manufacturing complexities, and long-term efficacy, the demonstrated effectiveness in clinical trials positions gene therapy as a significant research direction in oncology.
The cancer gene therapy market is rapidly evolving, driven by several key factors: First, the rising incidence of cancer and the limitations of traditional treatments have increased the demand for novel therapeutic options. Second, advancements in gene editing and cell engineering technologies have made the development and production of cancer gene therapies more feasible. Third, supportive policies from regulatory agencies regarding personalized and precision medicine have created a favorable environment for the clinical application of gene therapies. Fourth, patients' focus on efficacy and quality of life has driven the demand for innovative treatments. Additionally, collaborations between biopharmaceutical companies and research institutions have accelerated the translation of technologies and product development.
Despite the significant potential of cancer gene therapies, several challenges and risks persist. First, the high treatment costs, involving personalized cell processing and gene editing, increase the burden on patients and healthcare systems. Second, the manufacturing process is complex, encompassing cell collection, gene modification, expansion, and reinfusion, with any deviation potentially impacting efficacy and safety. Third, the long-term efficacy and potential side effects are not yet fully understood, requiring more clinical data for validation. Fourth, the regulatory approval processes are cumbersome and time-consuming, potentially delaying the market introduction of new therapies. Fifth, the market is highly competitive, with numerous companies and research institutions investing in R&D, leading to increased risks of technological and product homogeneity.
Downstream demand for cancer gene therapies is exhibiting the following trends: First, with the widespread adoption of precision medicine concepts, there is an increasing demand from patients and healthcare institutions for personalized treatment plans. Second, as efficacy data accumulates, more cancer patients, especially those with refractory or relapsed conditions, are considering gene therapies. Third, insurance companies and payers are gradually expanding coverage for gene therapies, reducing the financial burden on patients. Fourth, patients' concerns about treatment safety and quality of life are prompting research and development to focus more on controlling side effects and optimizing treatment regimens. Additionally, improvements in patient education and information access have enhanced acceptance of new therapies.
This report is a detailed and comprehensive analysis for global Gene Therapies for Cancer Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Gene Therapies for Cancer Treatment market size and forecasts, in consumption value ($ Million), 2021-2032
Global Gene Therapies for Cancer Treatment market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Gene Therapies for Cancer Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Gene Therapies for Cancer Treatment market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene Therapies for Cancer Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gene Therapies for Cancer Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Sunway Biotech, SIBIONO, AnGes, Orchard Therapeutics, Human Stem Cells Institute, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Gene Therapies for Cancer Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Viral Vectors
Non-viral Vectors
Market segment by Application
Solid Tumors
Hematologic Malignancies
Market segment by players, this report covers
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Gene Therapies for Cancer Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Therapies for Cancer Treatment, with revenue, gross margin, and global market share of Gene Therapies for Cancer Treatment from 2021 to 2026.
Chapter 3, the Gene Therapies for Cancer Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Gene Therapies for Cancer Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Therapies for Cancer Treatment.
Chapter 13, to describe Gene Therapies for Cancer Treatment research findings and conclusion.
Summary:
Get latest Market Research Reports on Gene Therapies for Cancer Treatment. Industry analysis & Market Report on Gene Therapies for Cancer Treatment is a syndicated market report, published as Global Gene Therapies for Cancer Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Gene Therapies for Cancer Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.